Dissecting the Roles of GABA and Neuropeptides from Rat Central Amygdala CRF Neurons in Anxiety and Fear Learning

Matthew B. Pomrenze1,3,4,*, Simone M. Giovanetti1,3, Rajani Malya1,3, Adam G. Gordon1,3, Lauren J. Kreeger1, Robert O. Messing1,2,3,5,*

1Department of Neuroscience, University of Texas at Austin, Austin, TX 78712, USA
2Department of Neurology, University of Texas at Austin, Austin, TX 78712, USA
3Waggoner Center for Alcohol and Addiction Research, University of Texas at Austin, Austin, TX 78712, USA
4Present address: Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA 94305, USA
5Lead Contact

SUMMARY

Central amygdala (CeA) neurons that produce corticotropin-releasing factor (CRF) regulate anxiety and fear learning. These CeA-CRF neurons release GABA and several neuropeptides predicted to play important yet opposing roles in these behaviors. We dissected the relative roles of GABA, CRF, dynorphin, and neurotensin in CeA-CRF neurons in anxiety and fear learning by disrupting their expression using RNAi in male rats. GABA, but not CRF, dynorphin, or neurotensin, regulates baseline anxiety-like behavior. In contrast, chemogenetic stimulation of CeA-CRF neurons evokes anxiety-like behavior dependent on CRF and dynorphin, but not neurotensin, regulates baseline anxiety-like behavior. In contrast, chemogenetic stimulation of CeA-CRF neurons evokes anxiety-like behavior dependent on CRF and dynorphin, but not neurotensin. Finally, knockdown of CRF and dynorphin impairs fear learning, whereas knockdown of neurotensin enhances it. Our results demonstrate distinct behavioral roles for GABA, CRF, dynorphin, and neurotensin in a subpopulation of CeA neurons. These results highlight the importance of considering the repertoire of signaling molecules released from a given neuronal population when studying the circuit basis of behavior.

Graphical Abstract

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

*Correspondence: pomrenze@stanford.edu (M.B.P.), romessing@austin.utexas.edu (R.O.M.).

AUTHOR CONTRIBUTIONS

M.B.P. conducted all behavioral and histological experiments and performed stereotaxic surgeries. S.M.G. generated shRNA constructs targeting peptides and performed qPCR experiments. R.M. assisted with behavioral experiments and performed western blotting. A.G.G. assisted with stereotaxic surgeries. L.J.K. contributed to validation of shRNA constructs. M.B.P. and R.O.M. designed the experiments and wrote the manuscript.

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at https://doi.org/10.1016/j.celrep.2019.08.083.

DECLARATION OF INTERESTS

The authors declare no competing interests.
In Brief

Pomrenze et al. demonstrate that CRF neurons of the central amygdala differentially regulate fear and anxiety through the release of GABA and different neuropeptides.

INTRODUCTION

Genetic tools that permit cell-type and pathway-specific targeting of tracers and actuators have provided unprecedented insight into how neural circuits control behavior (Yizhar et al., 2011). Cre-driver mouse lines and viral tools are typically used to manipulate the activity of neuronal subpopulations (Daigle et al., 2018). However, a pitfall of this approach lies in the temptation to attribute the actions of the manipulated subpopulation to the gene product, usually a neuropeptide or neurotransmitter, whose promoter was used to drive Cre recombinase expression while overlooking the contributions of other signaling molecules produced by the targeted neurons.

This complexity is particularly evident when deciphering circuit effects of neuropeptides. Essentially all neuropeptide neurons express more than one and release a fast-acting neurotransmitter such as glutamate or γ-aminobutyric acid (GABA) (Nusbaum et al., 2017; van den Pol, 2012). Compared with fast-acting neurotransmitters, neuropeptides may require higher-frequency stimulation and larger increases in intracellular calcium for release. Neuropeptides can also signal over longer distances because of extrasynaptic release, local diffusion, and the requirement of extracellular proteolytic cleavage as opposed to reuptake.
for signal termination. An interesting question is how multiple peptides released by a single neuron interact, particularly when they evoke initially opposing responses. Furthermore, determining how multiple neurotransmitter signals are integrated by postsynaptic cells to generate flexible physiological and behavioral outputs remains a significant challenge.

One brain structure rich in neuropeptides is the central amygdala (CeA), which contains a large population of GABAergic cells that express the stress-responsive neuropeptide corticotropin-releasing factor (CRF). CeA<sup>CRF</sup> neurons also express other neuropeptides such as dynorphin (DYN) and neurotensin (NTS), and when activated, they promote anxiety-like behavior and fear learning (Asok et al., 2018; Kim et al., 2017; McCall et al., 2015; Pliota et al., 2018; Pomrenze et al., 2015; Sanford et al., 2017). Despite CeA<sup>CRF</sup> neurons having established roles in fear and anxiety, the relative contribution of the individual neurotransmitters that they release has only been explored for CRF (McCall et al., 2015; Regev et al., 2012; Sanford et al., 2017).

In this study, we examined the question of how CeA<sup>CRF</sup> neurons control and fine-tune behavior through the release of diverse signaling molecules, some of which are predicted to have opposing actions. We examined the roles of CRF, GABA, and the co-expressed neuropeptides DYN and NTS by using RNAi in a rat line that expresses Cre recombinase under control of the CRF promoter (Pomrenze et al., 2015). Our results demonstrate that CeA<sup>CRF</sup> neurons play a multimodal role in regulating these behaviors through the coordinate actions of different neurotransmitters. These findings highlight the importance of considering the spectrum of signaling molecules expressed by a subpopulation of neurons when studying brain physiology and behavior.

**RESULTS**

**GABA in CeA<sup>CRF</sup> Neurons Regulates Baseline Anxiety-like Behavior**

An important question is whether GABA and neuropeptides released from CeA<sup>CRF</sup> neurons (Dabrowska et al., 2013; Pomrenze et al., 2015) cooperate to regulate behavior or play distinct roles. Because CRF is anxiogenic (Liang et al., 1992; Swerdlov et al., 1986) and activation of CeA<sup>CRF</sup> neurons can produce anxiety-like behavior in mice (McCall et al., 2015; Pliota et al., 2018; Regev et al., 2012), we hypothesized that GABA released from rat CeA<sup>CRF</sup> neurons would synergize with CRF to generate anxiety-like behavior. To test this hypothesis, we reduced vesicular GABA levels in these neurons (Figure S1G) by viral delivery of a Cre-dependent short hairpin RNA (shRNA) that targets the 3′ UTR of the transcript encoding the vesicular GABA transporter (Vgat) (Yu et al., 2015). After 4–6 weeks to allow adeno-associated virus (AAV) expression and knockdown, we tested rats for anxiety-like behavior. Surprisingly, we observed increased anxiety-like behavior in both elevated plus maze (EPM) and open-field (OF) tests in animals with Vgat knockdown compared with animals expressing a control shRNA (Figures 1B and 1C). There was no effect of Vgat knockdown on locomotion (Figures S2A and S2B). This finding suggests that GABA release from CeA<sup>CRF</sup> neurons is anxiolytic under baseline conditions.

Knockdown of Vgat in CeA<sup>CRF</sup> neurons could promote anxiety-like behavior through disinhibition of downstream circuits. To investigate this possibility, we challenged a separate
group of rats with \textit{Vgat} knockdown by placing them in the OF and used Fos as a readout for neural activity engaged by OF exposure (Figure 2A) (Heisler et al., 2007). Control rats exposed to the OF showed low levels of Fos in the CeA and the oval bed nucleus of the stria terminalis (BNST), a structure that is known to modulate anxiety and is strongly connected with the CeA as part of the extended amygdala (Swanson and Petrovich, 1998). In contrast to controls, rats with \textit{Vgat} knockdown displayed a large induction of Fos in both structures (Figures 2B–2E). Several Fos$^+$ neurons in the CeA and oval BNST expressed protein kinase C$\delta$ (PKC$\delta$), a marker for a subpopulation of non-CRF neurons that when activated can drive anxiety-like behaviors in mice (Botta et al., 2015). Altogether, these data suggest that CeA$^{\text{CRF}}$ neurons release GABA to dampen baseline anxiety-like behavior through inhibition of other subpopulations of neurons in the extended amygdala.

\textbf{CeA$^{\text{CRF}}$ Neuron Neuropeptides and Baseline Anxiety}

We have shown previously that rat CeA$^{\text{CRF}}$ neurons express several neuropeptides besides CRF (Pomrenze et al., 2015), consistent with other reports (Kim et al., 2017; Marchant et al., 2007). Pharmacological studies indicate that CRF and DYN are anxiogenic (Crowley et al., 2016; Knoll et al., 2011; Regev et al., 2012). However, because neuropeptide release typically requires high-frequency stimulation (van den Pol, 2012), we hypothesized that CRF and DYN play minor roles in baseline anxiety. To examine this question, we designed Cre-dependent shRNAs against the pro-peptides for CRF, DYN, and NTS (Figures S1A and S1B). The most effective shRNA sequences were packaged into AAV8 vectors and injected bilaterally into the CeA of Crh-Cre rats. After 4 weeks, we verified \textit{in vivo} knockdown of respective mRNAs by qPCR (Figures S1D and S1E).

Rats expressing these shRNAs were tested for baseline anxiety-like behavior. Compared with control rats, knockdown of each peptide modestly increased the percentage of open-arm entries but did not alter the percentage of time in the open arms of the EPM (Figure 1D). Knockdown also did not alter the time spent in the center or the number of entries into the center of the OF (Figure 1E). Locomotor activity was not altered in either test (Figures S2C and S2D). These findings indicate that CRF, DYN, and NTS in CeA$^{\text{CRF}}$ neurons play minor roles compared with GABA in setting the level of baseline anxiety.

\textbf{Activation of CeA$^{\text{CRF}}$ Neurons Promotes Anxiety-like Behavior through CRF and DYN}

CeA$^{\text{CRF}}$ neurons can evoke anxiety-like behavior when stimulated (McCall et al., 2015; Pliota et al., 2018), and overexpression of CRF in the CeA of rats and primates is anxiogenic (Kalin et al., 2016; Keen-Rhinehart et al., 2009). Therefore, we investigated whether CRF in CeA$^{\text{CRF}}$ neurons is necessary for the increased anxiety-like behavior observed when CeA$^{\text{CRF}}$ neurons are activated. We transduced CeA$^{\text{CRF}}$ neurons with a Cre-dependent excitatory designer receptor hM3Dq, together with the Cre-dependent shRNA against CRF (Figure 3A). All animals received an injection of the hM3Dq-specific ligand CNO (2 mg/kg intraperitoneally [i.p.]), which causes depolarization and large increases in spontaneous firing in CRF neurons that express hM3Dq (Pomrenze et al., 2019). Rats with CRF knockdown showed less anxiety-like behavior in the EPM compared with controls but no differences in the OF (Figures 3B and 3C). To investigate this unexpected result, we systemically administered the CRF1 receptor antagonist R121919 (20 mg/kg subcutaneously...
to rats expressing Cre-dependent hM3Dq 30 min before a CNO injection (2 mg/kg i.p.). Again, we observed that compared with controls, rats treated with CNO alone exhibited anxiety-like behavior in both tests, but rats treated with CNO and R121919 showed less anxiety-like behavior only in the EPM (Figure S3). These data indicate that CRF released from CeA\textsuperscript{CRF} neurons promotes anxiety-like behavior on the EPM, but not the OF.

The anxiogenic effect of central CRF administration depends on DYN signaling (Bruchas et al., 2009). To investigate whether anxiety-like behavior upon stimulation of CeA\textsuperscript{CRF} neurons depends on DYN, we repeated the preceding hM3Dq experiment but injected rats with the Cre-dependent shRNA targeting DYN. Compared with control animals, rats with DYN knockdown showed reduced anxiety-like behavior in both EPM and OF tests (Figures 3D and 3E).

Injection of an NTS receptor antagonist into the oval BNST prevents anxiety evoked by chronic unpredictable stress (Normandeau et al., 2018b). To determine whether NTS in CeA\textsuperscript{CRF} neurons contributes to hM3Dq-evoked anxiety, we activated CeA\textsuperscript{CRF} neurons in rats previously injected with Cre-dependent hM3Dq and shRNA against NTS. Knocking down NTS in CeA\textsuperscript{CRF} neurons did not alter behavior in the EPM or OF tests after stimulation with CNO (Figures 3F and 3G). Knockdown of these peptides did not alter locomotor activity in either test (Figures S2E–S2J), except for a slight reduction in closed-arm entries in rats with CRF knockdown (Figure S2E). These results indicate that CRF and DYN, but not NTS, in CeA\textsuperscript{CRF} neurons regulate hM3Dq-evoked anxiety-like behavior.

CRF, DYN, and NTS, but Not GABA, in CeA\textsuperscript{CRF} Neurons Modulate Fear Learning

CeA\textsuperscript{CRF} neurons contribute to fear learning in mice (Sanford et al., 2017) and rats (Asok et al., 2018). We confirmed this role by expressing the inhibitory designer receptor hM4Di in the CeA of Crh-Cre rats to silence the activity of CeA\textsuperscript{CRF} neurons. Rats were administered CNO (2 mg/kg i.p.) before or immediately after fear conditioning or before retrieval trials (Figures 4B and S4). All rats exhibited shock-induced freezing, but only those administered CNO during conditioning showed reduced freezing in subsequent contextual and cued retrieval trials (Figure 4B). Rats with CeA\textsuperscript{CRF} neuron inhibition immediately after conditioning or before retrieval trials exhibited no differences in contextual or cued freezing (Figure S4). These data confirm that CeA\textsuperscript{CRF} neurons contribute to fear learning and are relatively dispensable during expression tests once fear memory has been formed.

The contribution of CeA-derived CRF to fear learning is unclear. In mice, knockdown of CRF in the CeA had little effect on fear behavior (Regev et al., 2012), yet CRF knockout via Cre-mediated gene deletion disrupted fear acquisition to low unconditioned stimulus (US) intensities (Sanford et al., 2017). In rats, knockdown of CRF in the CeA impaired contextual fear memory consolidation (Pitts et al., 2009). Using our Cre-dependent shRNA targeting CRF, we found that CRF knockdown reduced freezing to the fear context and cues without altering shock-induced freezing during the conditioning session (Figure 4C). Therefore, in rats, CeA\textsuperscript{CRF} neurons are a major source of CRF that mediates fear learning.

DYN and NTS also influence fear learning but do so in opposite directions. Blockade of κ-opioid receptors in the amygdala decreases conditioned fear in rats (Fanselow et al., 1991;
Knoll et al., 2011). In contrast, NTS1 receptor knockout mice display enhanced fear expression (Yamada et al., 2010), and in rats, NTS receptor agonists reduce while antagonists increase conditioned fear behavior (Prus et al., 2014; Toda et al., 2014). The source of DYN and NTS involved in these responses is not known. Using our Cre-dependent shRNAs, we found that similar to knockdown of CRF, knockdown of DYN in CeA<sup>CRF</sup> neurons disrupted contextual and cued fear retrieval (Figure 4C). In contrast, knockdown of NTS in CeA<sup>CRF</sup> neurons enhanced cued fear retrieval without altering shock-induced freezing or contextual fear retrieval (Figure 4C). These results indicate that CeA<sup>CRF</sup> neurons are a major source of DYN and NTS that differentially regulate fear learning.

Because we found that GABA in CeA<sup>CRF</sup> neurons regulates baseline anxiety, we next asked whether it also plays a role in fear learning. Surprisingly, knockdown of Vgat in CeA<sup>CRF</sup> neurons had little effect on fear learning or expression (Figure 4D).

**DISCUSSION**

We were surprised to find that CRF neurons in the lateral CeA produce neurotransmitters with opposing roles on anxiety-like behavior. Under non-stressful conditions, GABA in these neurons was critically important for limiting baseline anxiety, while CRF, DYN, and NTS had little effect. However, CRF and DYN mediated anxiety-like behavior evoked by chemogenetic stimulation of these neurons. Both CRF and DYN are anxiogenic (Crowley et al., 2016; Knoll et al., 2011; McCaull et al., 2015; Regev et al., 2012), and our results indicate that their co-release from CeA<sup>CRF</sup> neurons is a mechanism by which they synergize to increase anxiety (Bruchas et al., 2009). In contrast, knockdown of NTS had no detectable effect on baseline or evoked anxiety, in agreement with prior work (László et al., 2010). Altogether, our results indicate that GABA and neuropeptides produced by CeA<sup>CRF</sup> neurons differentially regulate anxiety-like behavior under basal versus stimulated conditions. Studies are needed to determine whether increased basal anxiety in rats with GABA-deficient CeA<sup>CRF</sup> neurons is mediated by homeostatic increases in CRF or DYN tone.

We found that CRF knockdown or blockade of CRF1 receptors prevented hM3Dq-induced anxiety on the EPM, but not in the OF, whereas knockdown of DYN prevented anxiety-like behavior in both. The EPM might be less anxiogenic than the OF; the closed arms represent safety areas, whereas the OF offers less protection. We speculate that in animals with CRF knockdown, DYN in these neurons was sufficient to maintain anxiety in the OF, but not in the EPM.

When we used chemogenetics to inhibit CeA<sup>CRF</sup> neurons during fear conditioning, we found that these neurons contribute to fear learning, but not to fear retrieval, consistent with recent studies in mice (Sanford et al., 2017) and rats (Asok et al., 2018). Moreover, we found that knockdown of CRF or DYN in CeA<sup>CRF</sup> neurons disrupted contextual and cued fear retrieval, whereas knockdown of NTS enhanced cued retrieval. Our results are consistent with reports showing that CRF knockout or knockdown, or CRFR1 antagonism in the amygdala (Pitts et al., 2009; Sanford et al., 2017), disrupts fear learning. Our results are also consistent with reports showing that antagonists of κ-opioid receptors reduce fear behavior (Fanselow et al., 1991; Knoll et al., 2011) and antagonists of NTS1 receptors enhance fear.
behavior (Prus et al., 2014; Steele et al., 2017; Yamada et al., 2010). In these pharmacological studies, the source of DYN and NTS was not identified. Here, using the CRF gene as a cellular entry point, we have identified CeA^{CRF} neurons as an important source of DYN and NTS involved in fear learning.

Our results reveal an anxiolytic role for CeA^{CRF} neurons in the basal state that is mediated by GABA, which switches to an anxiogenic role mediated by CRF and DYN when these neurons are activated. Several mechanisms may explain how GABA and cotransmission of these neuropeptides could produce divergent behavioral responses. Unlike GABA, neuropeptides are stored in dense core vesicles and can be released somatodendritically (Iremonger and Bains, 2009) or stored and released axonally at non-synaptic sites (Atasoy et al., 2014). There is a firing-rate dependence to co-release, whereby neuropeptide release tends to require higher firing rates than are needed for small-molecule neurotransmitters like GABA (Nusbaum et al., 2017). These peptides may reside in different dense-core vesicles and may be localized in terminal fields different from those harboring small vesicles containing GABA. For example, activation of CRF neurons from the amygdala to the locus coeruleus can increase activity of noradrenergic neurons through a CRF-dependent process that is independent of fast neurotransmitter release (McCall et al., 2015). Moreover, differential distribution of GABA and neuropeptide receptors and their coupling to different signaling pathways can lead to divergent or convergent circuit responses. For example, CRF and NTS enhance presynaptic GABA release onto oval BNST neurons (Normandeau et al., 2018b), whereas DYN and NTS exhibit opposing control over evoked GABA release from CeA inputs to the oval BNST (Normandeau et al., 2018a). In addition, co-expressed receptors can have cooperative or antagonistic effects on synaptic transmission in target neurons, similar to what has been observed in dopamine neurons co-expressing CRF and α1-adrenergic receptors (Tovar-Díaz et al., 2018). How the co-release of multiple neurotransmitters coordinates circuit activity to achieve a specific behavioral outcome is clearly a complex and important question for future study.

In summary, our study demonstrates the versatility of CeA^{CRF} neurons in regulating fear and anxiety through different neurotransmitters. CRF and DYN promote fear and anxiety, whereas NTS suppresses fear and GABA constrains baseline anxiety in non-stressed conditions. These results indicate that CeA^{CRF} neurons are not restricted to subserving just one type of behavioral response. Furthermore, our findings suggest that CeA^{CRF} neurons, and perhaps the CRF system, interacts strongly with other neuropeptide systems. This property may have contributed to negative results from clinical trials evaluating effects of CRF receptor antagonists on stress-related alcohol craving and negative emotions associated with post-traumatic stress disorder (PTSD) (Dunlop et al., 2017; Kwako et al., 2015; Schwandt et al., 2016). It is our expectation that investigations like ours will improve understanding of how brain neuropeptide systems interact to regulate limbic circuits and behavior and contribute to the development of more effective combined therapeutic strategies for treating emotional disorders.
STAR★METHODS

LEAD CONTACT AND MATERIALS AVAILABILITY

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Robert O. Messing (romessing@austin.utexas.edu). Plasmids generated in this study have been deposited to Addgene for distribution to the research community.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Subjects—All procedures were approved by the University of Texas at Austin Institutional Animal Care and Use Committee. We used male hemizygous *Crhr*-Cre rats (Pomrenze et al., 2015) outcrossed to wild-type Wistar rats (Envigo, Houston, TX), aged 5–6 weeks at the start of the surgical procedures and 10–14 weeks at the start of experimental procedures. Rats were group housed and maintained on a 12-hr light:dark cycle with food and water available *ad libitum*. Cre⁺ rats were randomly assigned to either experimental or control groups within each litter.

METHOD DETAILS

Drugs and viral vectors—Clozapine-N-oxide (CNO) was supplied through the NIMH Chemical Synthesis and Drug Supply Program. CNO (2 mg/kg body weight) was dissolved in 5% dimethyl sulfoxide (DMSO) and then diluted to 2 mg/mL with 0.9% saline. Systemic injections were administered at 1 mL/kg. The selective CRF1 receptor antagonist 3-[6-(dimethylamino)-4-methyl-pyrid-3-yl]-2,5-dimethyl-N,N-dipropyl-pyrazolo[2,3-alpyrimidin-7-amine (R121919) was provided by Dr. Kenner Rice (Drug Design and Synthesis Section, NIDA, Bethesda, MD) and dissolved in a 1:1 solution of 0.9% saline and 1N HCl before adding 25% hydroxypropyl-β-cyclodextrin (HBC; Sigma Aldrich, St. Louis, MO) to yield a final concentration of 10 mg/mL R121919 in 20% HBC, pH 4.5. R121919 injections were administered at 2 mL/kg.

The Cre-dependent viral vector AA V8-hSyn-DIO-hM3Dq-mCherry was obtained from Addgene (Cambridge, MA). AAV constructs containing shRNAs targeting Vgat, proCrh, prodynorphin, neurotensin, and a control were packaged by the University of North Carolina Chapel Hill viral vector core. All AAVs were injected at 4–6 × 10¹² infectious units per mL.

Stereotaxic surgery—Rats weighing 200–250 g were anesthetized with isoflurane (5% v/v) and secured in a stereotaxic frame (David Kopf Instruments, Tujunga, CA). Viruses were injected bilaterally into the CeA (AP: −2.2; ML: ± 4.5; DV: −8.0 from skull) at a rate of 150 nL min⁻¹ for 5 min (750–800nL total volume per hemisphere) with a custom 32-gauge injector cannula coupled to a pump-mounted 2μL Hamilton syringe. Injectors were slowly retracted after a 5 min diffusion period. Rats were group housed to recover for 4–6 weeks before experiments began.

Generation of shRNAs—We designed shRNAs targeting the 3′ untranslated regions (UTR) of rat *proCrh*, *prodynorphin*, or *neurotensin* and subcloned them into a pPRIME vector containing a modified microRNA (*miR*30) cassette (Addgene #11657) for *in vitro*
validation of knockdown. The 22-mer oligonucleotide 3′-untranslated sequences used to generate shRNAs were:

- **shCrh1**: AACACAGTATTCTGTACCATAC
- **shCrh2**: AAGTGTGTTTCTTTGTAGTAAC
- **shDyn1**: TACACTGAGCCTCGTTCTCCAT
- **shDyn2**: AGCTCTTCATGTGTTCTGAAAT
- **shNts1**: ACATGTGATTCTCATCCTTTAC
- **shNts2**: TACCTGTTATCTGGATACACAT

The **miR30** cassette with the most effective shRNA sequence for each peptide was then subcloned into a Cre-dependent (**flex**) pAAV vector (Addgene #67845). A previously validated Cre-dependent shRNA targeting the 3′-UTR of the vesicular GABA transporter (**Vgat**) and a control shRNA targeting luciferase within the same **miR30** cassette were gifts from Dr. William Wisden (Imperial College, London, UK; Yu et al., 2015). These constructs were packaged into AAV8 by the UNC Viral Vector Core. AAV8-hSyn-**flex-eGFP-shCrh**, AAV8-hSyn-**flex-eGFP-shDyn**, AAV8-hSyn-**flex-eGFP-shNts**, AAV8-hSyn-**flex-eGFP-shVgat**, and AAV8-hSyn-**flex-eGFP-shControl** were injected at 2–3 × 10^{12} particles per mL. *In vivo* knockdown was verified using RT-qPCR from AAV-infected CeA tissue punches.

**RT-qPCR—**Crr-Cre rats were bilaterally injected into the CeA with AAVs carrying shCrh, shDyn, shNts, or shCon. After 4 weeks, rats were euthanized and their brains flash frozen in isopentane on dry ice and stored at −80°C. Brains were then equilibrated to −20°C in a cryostat for 1 hr and the CeA sectioned coronally at 250 μm and mounted onto cold Superfrost Plus slides (Fisher Scientific). Tissue punches (2 mm) spanning the CeA of both hemispheres were collected on dry ice and snap frozen in liquid nitrogen. RNA was extracted immediately using RNeasy Lipid Tissue Mini Kit (QIAGEN, Hilden, Germany). Purified RNA samples were reverse transcribed using the High Capacity cDNA Synthesis Kit (Invitrogen, Carlsbad, CA). Quantitative real-time PCR was performed using a TaqMan Gene Expression Assay Kit (Applied Biosystems, Foster City, CA). All TaqMan probes were purchased from Applied Biosystems: **Crh** (Rn01462137_m1), **pDyn** (Rn00571351_m1), **Nts** (Rn01503265_m1), and **GusB** (Rn00566655_m1). Target amplification was performed using a ViiA 7 Real-Time PCR System (Applied Biosystems). Relative mRNA expression levels were calculated using a comparative threshold cycle (**Ct**) method with **GusB** as an internal control: \( \Delta C_t = C_t (\text{gene of interest}) - C_t (\text{GusB}) \). The gene expression fold change was normalized to the control sample and then was calculated as \( 2^{-\Delta \Delta C_t} \).

**Western blotting—**shRNA-mediated knockdown was tested *in vitro* using HEK293 cells. Cells were plated at a density of 3 × 10^5 cells/well in 12-well plates. Twenty-four hours after plating, cells were co-transfected with a pPRIME vector and a corresponding transgene encoding CRF or DYN (including their 3′-UTRs) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Sixty hours after transfection, media was aspirated and cells were lysed by incubating with 200μl of ice-cold RIPA buffer at 4°C for 30 min. The lysate was then
centrifuged at 10,000 × g for 15 min at 4°C. Supernatant was collected and protein concentrations were measured using the bicinchoninic assay method (Life Technologies). Samples (40 μg) were resolved on a 10% SDS polyacrylamide gel and proteins were then transferred onto a nitrocellulose membrane. After transfer, the membrane was blocked with 5% milk in Tris-buffered saline containing 0.01% Tween-20 (TBST). The blot was probed with 1:200 dilution of goat anti-CRF antibody (Santa Cruz Biotechnology, Dallas, TX, sc-1761) or 1:1000 dilution of guinea pig anti-DYN antibody (Neuromics, GP10110) in 5% milk overnight at 4°C with shaking. Blots were washed three times in 1X TBST and probed with 1:2500 dilution (in 5% milk) of horseradish peroxidase conjugated anti-goat or anti-guinea pig secondary antibodies (Santa Cruz Biotechnologies) for 1 hr at room temperature followed by chemiluminescent detection (Super-signal West, Life Technologies). Blots were stripped (Restore buffer, Life Technologies) and probed with anti-rabbit GAPDH (1:10,000 dilution in 5% milk, Cell Signaling Technologies, 5174S). Immunoreactive bands were quantified using Fiji (Schindelin et al., 2012). CRF and DYN levels were normalized to GAPDH and percent knockdown was calculated.

Behavior—We used two assays to evaluate anxiety-like behavior: the elevated plus maze (EPM) and the open field (OF) tests. The EPM consisted of two open arms (50 × 10 cm) and two enclosed arms (50 × 10 × 40 cm) connected by a central area measuring 10 × 10 cm, 50 cm above the floor. At the beginning of each trial, rats were placed in the center facing one open arm. Trials lasted for 5 min and were performed under red lighting. The OF consisted of an open topped arena (100 × 100 × 50 cm) situated on the floor. The center zone measured 55 × 55 cm. Rats were placed into a corner of the arena at the beginning of each trial. Each trial lasted 10 min and was performed under red lighting. All testing equipment was cleaned with 70% ethanol between trials. Behaviors were tracked with EthoVision (Noldus Information Technology, Leesburg, VA, USA).

Rats were subjected to a typical fear conditioning protocol with 3 CS-US (tone-shock) pairings (75 dB, 5 kHz, 20 s tones co-terminating with 0.7 mA, 500 ms shocks, variable ITI (average 180 s)) for delay conditioning (Monfils et al., 2009; Schafe et al., 1999). Twenty-four hours later rats were tested for contextual fear retrieval by being placed back into the original fear context for 5 min. Another 24 hr later rats were tested for cued fear retrieval in a distinct context with the presentation of 4 CS tones. The distinct context consisted of pinstripe and checkered walls, smooth floors, and the scent of 1% acetic acid.

Histology—Rats were anesthetized with isoflurane and perfused transcardially with PBS followed by 4% paraformaldehyde in PBS, pH 7.4. Brains were extracted, post-fixed overnight in the same fixative and cryoprotected in 30% sucrose in PBS at 4°C. Brains were sectioned at 40μm on a cryostat and collected in PBS. Free-floating sections were washed three times in PBS with 0.2% Triton X-100(PBST) for 10 min at 27°C and then incubated in PBST with 3% normal donkey serum (Jackson ImmunoResearch, West Grove, PA, Cat. No. 017-000-121) for 1 hr. Sections were next incubated in goat anti-cFos (1:2000, Santa Cruz Biotechnology, sc-52-G) and rabbit anti-PKCeδ (1:2000, Santa Cruz Biotechnology, sc-213) in blocking solution rotating at 4°C for 18–20 hr. After three 10 min washes in PBST, sections were incubated in species-specific secondary antibodies Alexa Fluor 594 and 647.
(1:700, Invitrogen, Carlsbad, CA, A-11058 and A-31573) in blocking solution for 1h at 27°C. Finally, sections were washed three times for 10 min in 1X PBS, mounted in 0.2% gelatin onto SuperFrost Plus glass slides, and coverslipped with Fluoromount-G with DAPI (Southern Biotech, Birmingham, AL, 0100–20). Fluorescent images were collected on a Zeiss 710 confocal microscope or a Zeiss AxioZoom stereo microscope. Quantification of fluorescence was performed on 3–6 sections per rat from approximately Bregma −1.90 to −3.00 in the CeA and Bregma +0.2 to −0.2 in the oval BNST using the cell-counter plugin in Fiji (Schindelin et al., 2012).

**Fluorescence in situ hybridization**—For examination of Vgat expression in the CeA, coronal sections were processed for fluorescent in situ hybridization by RNAscope according to manufacturer’s guidelines. Genes examined in the CeA were Vgat (ACDBio cat# 424541), Cth (ACDBio cat# 318931), and viral-mediated egfp (ACDBio cat# 409971), and hybridization was performed using RNAscope Fluorescent Multiplex Kit (Advanced Cell Diagnostics). Slides were coverslipped with Fluoromount-G with DAPI (Southern Biotech, 0100–20) and stored at 4°C in the dark before imaging. Vgat puncta were counted selectively in egfp+ cells using the cell-counter plugin in Fiji (Schindelin et al., 2012).

**QUANTIFICATION AND STATISTICAL ANALYSIS**

We calculated sample sizes of n = 8–12 animals per condition using SD values measured in pilot studies of anxiety-like behavior, α = 0.05, and power = 0.80, with the goal of detecting at least a 25% difference in mean values for treated and control samples, using G*Power (Faul et al., 2007). All results were expressed as mean ± SEM values and analyzed using Prism 7.0 (GraphPad Software, San Diego, CA). Data distribution and variance were tested using Shapiro-Wilk normality tests. Normally distributed data were analyzed by unpaired, two-tailed t tests, or one or two factor ANOVA with post hoc Tukey’s or Bonferroni’s tests. Data that were not normally distributed were analyzed by Mann-Whitney U tests when comparing two conditions. Differences were considered significant when p < 0.05.

**DATA AND CODE AVAILABILITY**

The published article includes all data generated or analyzed during this study. This study did not generate code.

**Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.

**ACKNOWLEDGMENTS**

This work was supported by NIH grant AA026075 (to R.O.M.) and by Graduate Research Fellowship DGE-1110007 from the National Science Foundation (to M.B.P.). The authors thank Holly Chapman for help with data collection.

**REFERENCES**

Asok A, Draper A, Hoffman AF, Schulkin J, Lupica CR, and Rosen JB (2018). Optogenetic silencing of a corticotropin-releasing factor pathway from the central amygdala to the bed nucleus of the stria terminalis disrupts sustained fear. Mol. Psychiatry 23, 914–922. [PubMed: 28439099]
Atasoy D, Betley JN, Li W-PP, Su HH, Sertel SM, Scheffer LK, Simpson JH, Fetter RD, and Sternson SM (2014). A genetically specified connectomics approach applied to long-range feeding regulatory circuits. Nat. Neurosci 17, 1830–1839. [PubMed: 25362474]

Botta P, Demoulo L, Kasugai Y, Markovic M, Xu C, Fadok JP, Lu T, Poe MM, Xu L, Cook JM, et al. (2015). Regulating anxiety with extrasynaptic inhibition. Nat. Neurosci 18, 1493–1500. [PubMed: 26322928]

Bruchas MR, Land BB, Lemos JC, and Chavkin C (2009). CRF1-R activation of the dynorphin/kappa opioid system in the mouse basolateral amygdala mediates anxiety-like behavior. PLoS ONE 4, e8528. [PubMed: 20052275]

Crowley NA, Bloodgood DW, Hardaway JA, Kendra AM, McCall MM, Al-Hasani R, McCall NM, Yu W, Schools ZL, Krashes MJ, et al. (2016). Dynorphin controls the gain of an amygdalar anxiety circuit. Cell Rep. 14, 2774–2783. [PubMed: 26997280]

Dabrowska J, Hazra R, Guo JD, Dewitt S, and Rainnie DG (2013). Central CRF neurons are not created equal: phenotypic differences in CRF-containing neurons of the rat paraventricular hypothalamus and the bed nucleus of the stria terminalis. Front. Neurosci 7, 156. [PubMed: 24009552]

Daigle TL, Madisen L, Hage TA, Valley MT, Knoblich U, Larsen RS, Takeno MM, Huang L, Gu H, Larsen R, et al. (2018). A Suite of Transgenic Driver and Reporter Mouse Lines with Enhanced Brain-Cell-Type Targeting and Functionality. Cell 174, 465–480.e22. [PubMed: 30007418]

Dunlop BW, Binder EB, losifescu D, Mathew SJ, Neylan TC, Pape JC, Carrillo-Roa T, Green C, Kinkead B, Grigoriadis D, et al. (2017). Corticotropin-Releasing Factor Receptor 1 Antagonism Is Ineffective for Women With Posttraumatic Stress Disorder. Biol. Psychiatry 82, 866–874. [PubMed: 28793974]

Fanselow MS, Kim JJ, Young SL, Calcagnetti DJ, DeCola JP, Helmstetter FJ, and Landeira-Fernandez J (1991). Differential effects of selective opioid peptide antagonists on the acquisition of pavlovian fear conditioning. Peptides 12, 1033–1037. [PubMed: 1686930]

Faul F, Erdfelder E, Lang AG, and Buchner A (2007). G*Power3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav. Res. Methods 39, 175–191. [PubMed: 17695343]

Heisler LK, Zhou L, Bajwa P, Hsu J, and Tecott LH (2007). Serotonin 5-HT(2C) receptors regulate anxiety-like behavior. Genes Brain Behav. 6, 491–496. [PubMed: 17451451]

Iremonger KJ, and Bains JS (2009). Retrograde opioid signaling regulates glutamatergic transmission in the hypothalamus. J. Neurosci 29, 7349–7358. [PubMed: 19494156]

Kalim NH, Fox AS, Kovner R, Riedel MK, Fekete EM, Tromp do PM, Grabow BP, Olsen ME, Brodsky EK, et al. (2016). Overexpressing Corticotropin-Releasing Factor in the Primate Amygdala Increases Anxious Temperament and Alters Its Neural Circuit. Biol. Psychiatry 80, 345–355. [PubMed: 27016385]

Keen-Rhinehart E, Michopoulos V, Toufexis DJ, Martin EI, Nair H, Ressler KJ, Davis M, Owens MJ, Nemerooff CB, and Wilson ME (2009). Continuous expression of corticotropin-releasing factor in the central nucleus of the amygdala emulates the dysregulation of the stress and reproductive axes. Mol. Psychiatry 14, 37–50. [PubMed: 18698320]

Kim J, Zhang X, Muralidhara S, LeBlanc SA, and Tonegawa S (2017). Basolateral to central amygdala neural circuits for appetitive behaviors. Neuron 93, 1464–1479.e5. [PubMed: 28334609]

Knoll AT, Muschamp JW, Sillivan SE, Ferguson D, Dietz DM, Meloni EG, Carroll FI, Nestler EJ, Konradi C, and Carlezon WA Jr. (2011). Kappa opioid receptor signaling in the basolateral amygdala regulates conditioned fear and anxiety in rats. Biol. Psychiatry 70, 425–433. [PubMed: 21531393]

Kwako LE, Spagnolo PA, Schwandt ML, Thorsell A, George DT, Momenan R, Rio DE, Huestis M, Anizan S, Concheiro M, et al. (2015). The corticotropin releasing hormone-1 (CRH1) receptor antagonist pexacerfont in alcohol dependence: a randomized controlled experimental medicine study. Neuropsychopharmacology 40, 1053–1063. [PubMed: 25409596]

László K, Tóth K, Kertes E, Péczely L, and Lénárd L (2010). The role of neurotensin in positive reinforcement in the rat central nucleus of amygdala. Behav. Brain Res 208, 430–435. [PubMed: 20035801]
Liang KC, Melia KR, Miserendino MJ, Falls WA, Campeau S, and Davis M (1992). Corticotropin-releasing factor: long-lasting facilitation of the acoustic startle reflex. J. Neurosci 12, 2303–2312. [PubMed: 1351540]

Marchant NJ, Densmore VS, and Osborne PB (2007). Coexpression of prodynorphin and corticotrophin-releasing hormone in the rat central amygdala: evidence of two distinct endogenous opioid systems in the lateral division. J. Comp. Neurol 504, 702–715. [PubMed: 17722034]

McCall JG, Al-Hasani R, Siuda ER, Hong DY, Norris AJ, Ford CP, and Bruchas MR (2015). CRH engagement of the locus coeruleus noradrenergic system mediates stress-induced anxiety. Neuron 87, 605–620. [PubMed: 26212712]

Monfils MH, Cowansage KK, Klann E, and LeDoux JE (2009). Extinction-reconsolidation boundaries: key to persistent attenuation of fear memories. Science 324, 951–955. [PubMed: 19342552]

Normandeau CP, Torruella Suarez ML, Sarret P, McElligott ZA, and Dumont EC (2018a). Neurotensin and dynorphin Bi-Directionally modulate CeA inhibition of oval BNST neurons in male mice. Neuropearmacology 143, 113–121. [PubMed: 30248304]

Normandeau CP, Ventura-Silva AP, Hawken ER, Angelis S, Sjaarda C, Liu X, Pego JM, and Dumont EC (2018b). A key role for neurotensin in chronic-stress-induced anxiety-like behavior in rats. Neupropsychopharmacology 43, 285–293. [PubMed: 28649992]

Nusbaum MP, Blitz DM, and Marder E (2017). Functional consequences of neuropeptideand small-molecule co-transmission. Nat. Rev. Neurosci 18, 389–403. [PubMed: 28592905]

Pitts MW, Todorovic C, Blank T, and Takahashi LK (2009). The central nucleus of the amygdala and corticotropin-releasing factor: insights into contextual fear memory. J. Neurosci 29, 7379–7388. [PubMed: 19494159]

Pliota P, Böhm V, Grössl F, Griessner J, Valenti O, Kraists K, Kaczanowska J, Pasieka M, Lendl T, Deussing JM, and Haubensak W (2018). Stress peptides sensitize fear circuitry to promote passive coping. Mol. Psychiatry. Published online June 14, 2018. 10.1038/s41380-41018-40089-41382.

Pomrenze MB, Millan EZ, Hopf FW, Keiflin R, Maiya R, Blasio A, Dadgar J, Kharazia V, De Guglielmo G, Crawford E, et al. (2015). A transgenic rat for investigating the anatomy and function of corticotropin releasing factor circuits. Front. Neurosci 9, 487. [PubMed: 26733798]

Pomrenze MB, Tovar-Diaz J, Blasio A, Maiya R, Giovanetti SM, Lei K, Morikawa H, Hopf FW, and Messing RO (2019). A corticotropin releasing factor network in the extended amygdala for anxiety. J. Neurosci 39, 1030–1043. [PubMed: 30530860]

Prus AJ, Hillhouse TM, and LaCrosse AL (2014). Acute, but not repeated, administration of the neurotensin NTS1 receptor agonist PD149163 decreases conditioned footshock-induced ultrasonic vocalizations in rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 49, 78–84. [PubMed: 24275076]

Regev L, Tsoory M, Gil S, and Chen A (2012). Site-specific genetic manipulation of amygdala corticotropin-releasing factor reveals its imperative role in mediating behavioral response to challenge. Biol. Psychiatry 71, 317–326. [PubMed: 21783178]

Sanford CA, Soden ME, Baird MA, Miller SM, Schulkin J, Palmiter RD, Clark M, and Zweifel LS (2017). Acentral amygdala CRF circuit facilitates learning about weak threats. Neuron 93, 164–178. [PubMed: 28017470]

Schafe GE, Nadel NV, Sullivan GM, Harris A, and LeDoux JE (1999). Memory consolidation for contextual and auditory fear conditioning is dependent on protein synthesis, PKA, and MAP kinase. Learn Mem 6, 97–110. [PubMed: 10327235]

Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, et al. (2012). Fiji: an open-source platform for biological-image analysis. Nat. Methods 9,676–682. [PubMed: 22743772]

Schwandt ML, Cortes CR, Kwako LE, George DT, Momenan R, Sinha R, Grigoriadis DE, Pich EM, Leggio L, and Heilig M (2016). The CRF1 Antagonist Verucerfont in Anxious Alcohol-Dependent Women:Translation of Neuroendocrine, But not of Anti-Craving Effects. Neupropsychopharmacology 41, 2818–2829. [PubMed: 27109623]

Steele FF 3rd, Whitehouse SC, Aday JS, and Prus AJ (2017). Neurotensin NTS1 and NTS2 receptor agonists produce anxiolytic-like effects in the 22-kHz ultrasonic vocalization model in rats. Brain Res. 1658, 31–35. [PubMed: 28089664]
Swanson LW, and Petrovich GD (1998). What is the amygdala? Trends Neurosci. 21, 323–331. [PubMed: 9720596]

Swerdlow NR, Geyer MA, Vale WW, and Koob GF (1986). Corticotropin-releasing factor potentiates acoustic startle in rats: blockade by chlordiazepoxide. Psychopharmacology (Berl.) 88, 147–152. [PubMed: 3081925]

Toda H, Boku S, Nakagawa S, Inoue T, Kato A, Takamura N, Song N, Nibuya M, Koyama T, and Kusumi I (2014). Maternal separation enhances conditioned fear and decreases the mRNA levels of the neurotensin receptor 1 gene with hypermethylation of this gene in the rat amygdala. PLoS ONE 9, e97421. [PubMed: 24831231]

Tovar-Díaz J, Pomrenze MB, Kan R, Pahlavan B, and Morikawa H (2018). Cooperative CRF and α1 adrenergic signaling in the VTA promotes NMDA plasticity and drives social stress enhancement of cocaine conditioning. Cell Rep. 22, 2756–2766. [PubMed: 29514102]

van den Pol AN (2012). Neuropeptide transmission in brain circuits. Neuron 76, 98–115. [PubMed: 23040809]

Yamada D, Wada E, Amano T, Wada K, and Sekiguchi M (2010). Lack of neurotensin type 1 receptor facilitates contextual fear memory depending on the memory strength. Pharmacol. Biochem. Behav 96, 363–369. [PubMed: 20600248]

Yizhar O, Fenno LE, Davidson TJ, Mogri M, and Deisseroth K (2011). Optogenetics in neural systems. Neuron 71, 9–34. [PubMed: 21745635]

Yu X, Ye Z, Houston CM, Zecharia AY, Ma Y, Zhang Z, Uygun DS, Parker S, Vyssotski AL, Yustos R, et al. (2015). Wakefulness is governed by GABA and histamine cotransmission. Neuron 87, 164–178. [PubMed: 26094607]
Highlights

- Central amygdala CRF neurons release GABA and several neuropeptides
- Preventing GABA release in these neurons suppresses basal anxiety-like behavior
- Knockdown of CRF or dynorphin prevents anxiety evoked by chemogenetic activation
- CRF or dynorphin knockdown reduces but neurotensin knockdown enhances fear learning
Figure 1. Knockdown of VGAT, but Not Neuropeptides, in CeA\textsuperscript{CRF} Neurons Increases Anxiety-like Behavior

(A) Injection schematic and representative image of bilateral AAV infection in CeA\textsuperscript{CRF} neurons (DAPI counterstain). Scale bar, 500 μm.

(B) Knockdown of VGAT in CeA\textsuperscript{CRF} neurons reduced time spent in the open arms (t(22) = 3.158, **p = 0.0046; n = 12 for both groups) and entries into the open arms (t(22) = 7.858, ****p < 0.0001; n = 12 for both groups) on the elevated plus maze (EPM).

(C) Knockdown of VGAT reduced time spent in the center (t(22) = 2.156, *p = 0.0423; n = 12 for both groups) and entries into the center (t(22) = 2.407, *p = 0.0249; n = 12 for both groups) of the open field (OF).

(D) Knockdown of CRF, DYN, or NTS did not change time spent in the open arms of the EPM (F(3,39) = 0.5965, p = 0.6211, one-way ANOVA; n = 13 shCon, 11 shCrh, 10, shDyn, and 9 shNts) but did increase the number of entries into the open arms (F(3,39) = 2.139, p = 0.0092, one-way ANOVA; n = 13 shCon, 11 shCrh, 10, shDyn, and 9 shNts; *p < 0.05 compared with shCon by Dunnett’s test).

(E) Knockdown of CRF, DYN, or NTS did not change baseline anxiety-like behavior in the open field (time in the center: F(3,39) = 1.610, p = 0.2026; entries into the center: F(3,39) = 1.477, p = 0.2356; n = 13 shCon, 11 shCrh, 10, shDyn, and 9 shNts).

Data are represented as mean ± SEM.
Figure 2. Knockdown of VGAT in CeA\textsuperscript{CRF} Neurons Disinhibits Activation of the Extended Amygdala during Open-Field Exposure

(A) Left, viral injection schematic. Right, experimental protocol.

(B) Top, knockdown of VGAT in CeA\textsuperscript{CRF} neurons increased Fos expression in the CeA after open-field exposure ($F_{\text{shVgat} \times \text{OF}}(1,11) = 5.604, p = 0.0212; n = 3–4$; **$p = 0.0025$ for shVgat in the home cage [HC] compared with shVgat in the open field [OF] and **$p = 0.0015$ for shCon:OF compared with shVgat:OF by Tukey’s tests). Bottom, several Fos$^+$ neurons also expressed PKCδ.

(C) Representative images demonstrating increased Fos expression in the CeA of rats expressing sh Vgat in CeA\textsuperscript{CRF} neurons. Scale bars, 200 and 50 $\mu$m in the insets.
(D) Top, knockdown of VGAT in CeA<sup>CRF</sup> neurons increased Fos expression in the oval BNST after open-field exposure (F<sub>shVgat × OF</sub>(1,12) = 5.604, p = 0.0356; n = 4; ***p = 0.0009 for shVgat:HC compared with shVgat:OF and **p = 0.0011 for shCon:OF compared with shVgat:OF by Tukey’s tests). Bottom, several Fos<sup>+</sup> neurons also expressed PKCδ.

(E) Representative images demonstrating increased Fos expression in the oval BNST of rats expressing shVgat in CeA<sup>CRF</sup> neurons. EGFP<sup>+</sup> axons emerging from CeA<sup>CRF</sup> neurons are visible in the oval nucleus. Scale bars, 200 μm.

Data are represented as mean ± SEM.
Figure 3. CRF and Dynorphin, but Not Neurotensin, in Activated CeA\textsuperscript{CRF} Neurons Mediate Anxiety-like Behavior

(A) Top, example image of dual infection of CeA\textsuperscript{CRF} neurons with a cocktail of AAVs carrying shRNA and hM3Dq. Scale bar, 200 μm. Bottom, experimental protocol.

(B) Knockdown of CRF led to more time spent on the open arms (t(17) = 3.613, **p = 0.0021; n = 9 shCon and 10 shCrh) and more entries into the open arms (t(17) = 6.468, ****p < 0.0001; n = 9 shCon and 10 shCrh) of the elevated plus maze after activation of CeA\textsuperscript{CRF} neurons with hM3Dq and CNO (2 mg/kg i.p.).

(C) Knockdown of CRF did not alter anxiety-like behavior in the open field (center time: t(17) = 0.854, p = 0.5669; center entries: t(17) = 0.208, p = 0.8376; n = 9 shCon and 10 shCrh) after activation of CeA\textsuperscript{CRF} neurons with hM3Dq and CNO (2 mg/kg i.p.).
(D) Knockdown of DYN led to more time spent on the open arms ($t(18) = 5.151$, $****p < 0.0001$; $n = 9$ shCon and 11 shDyn) and more entries into the open arms ($t(18) = 5.589$, $****p < 0.0001$; $n = 9$ shCon and 10 shDyn) of the elevated plus maze after activation of CeA$^{\text{CRF}}$ neurons.

(E) Knockdown of DYN led to more time spent in the center ($U = 15$, $**p = 0.0074$; $n = 9$ shCon and 11 shDyn) and more entries into the center ($U = 17.5$, $*p = 0.013$; $n = 9$ shCon and 11 shDyn) of the open field after activation of CeA$^{\text{CRF}}$ neurons.

(F) Knockdown of NTS did not change the time spent on the open arms ($t(17) = 0.4315$, $p = 0.6716$; $n = 10$ shCon and 9 shNts) or entries into the open arms ($t(17) = 0.5536$, $p = 0.5871$; $n = 10$ shCon and 9 shNts) of the elevated plus maze after activation of CeA$^{\text{CRF}}$ neurons.

(G) Knockdown of NTS did not change the time spent in the center ($U = 30$, $p = 0.2428$; $n = 10$ shCon and 9 shNts) and more entries into the center ($t(17) = 1.319$, $p = 0.2046$; $n = 10$ shCon and 9 shNts) of the open field after activation of CeA$^{\text{CRF}}$ neurons.

Data are represented as mean ± SEM.
Figure 4. CRF, Dynorphin, and Neurotensin in CeA CRF Neurons Modulate Fear Learning

(A) Injection schematics and example of viral expression in CeA CRF neurons infected with hM4Di-mCherry DREADD (left) and shRNA with EGFP (right). Scale bar, 200 μm.

(B) Top, experimental protocol for fear conditioning. Bottom, chemogenetic inhibition of CeA CRF neurons with hM4Di and CNO (2 mg/kg i.p.) did not affect freezing during fear conditioning but disrupted contextual fear retrieval during the first minute (U = 1, ***p = 0.0003; n = 8 for both groups), as well as cued fear retrieval (t(14) = 4.846, ***p = 0.0003; n = 8 for both groups).

(C) Top, experimental protocol. Bottom, shRNA-mediated knockdown of CRF and DYN, but not NTS, in CeA CRF neurons blunted contextual fear retrieval during the first minute (F(3,38) = 12.53, p < 0.0001, one-way ANOVA; n = 13 shCon, 11 shCrh, 9 shDyn, and 9 Pomrenze et al. Page 21

Cell Rep. Author manuscript; available in PMC 2019 November 26.
shNts; ***p<0.0001 shCrh compared with shCon and **p = 0.0054 shDyn compared with shCon by Dunnett’s test). Knockdown of CRF and DYN also reduced cued freezing, yet knockdown of NTS enhanced cued freezing (F(3,39) = 34.13, p < 0.0001; n = 13 shCon, 11 shCrh, 10 shDyn, and 9 shNts; ****p < 0.0001 shCrh compared with shCon, ****p < 0.0001 shDyn compared with shCon, and *p = 0.0115 shNts compared with shCon by Dunnett’s test).

(D) Knockdown of Vgat in CeA\textsuperscript{CRF} neurons did not affect contextual fear learning (t(13) = 0.6684, p = 0.5156; n = 8 shCon and 7 shVgat) or cued fear learning (t(13) = 0.0125, p = 0.9902; n = 8 shCon and 7 shVgat).

Data are represented as mean ± SEM.
### KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Antibodies**      |        |            |
| Goat polyclonal anti-cFos | Santa Cruz Biotechnology | Cat# sc-52-G; RRID:AB_2629503 |
| Rabbit polyclonal anti-PKCdelta | Santa Cruz Biotechnology | Cat# sc-213; RRID:AB_632228 |
| Goat polyclonal anti-CRF | Santa Cruz Biotechnology | Cat# sc-1761; RRID:AB_631299 |
| Guinea pig polyclonal anti-Dynorphin | Neurons | Cat# GP10110; RRID:AB_1621439 |
| Donkey anti-goat Alexa Fluor 594 | Invitrogen | Cat# A-11058; RRID:AB_142540 |
| Donkey anti-rabbit Alexa Fluor 647 | Invitrogen | Cat# A-31573; RRID:AB_2536183 |
| Anti-rabbit GAPDH | Cell Signaling | Cat# 5174S; RRID:AB_10622025 |
| **Bacterial and Virus Strains** |        |            |
| AAV8-hSyn-DIO-hM3Dq-mCherry | Addgene | 44361 |
| AAV8-hSyn-flex-miR30-eGFP-shVgat | Yu et al., 2015 | N/A |
| AAV8-hSyn-hex-miR30-eGFP-shCrh | This paper | N/A |
| AAV8-hSyn-flex-miR30-eGFP-shDyn | This paper | N/A |
| AAV8-hSyn-flex-miR30-eGFP-shNts | This paper | N/A |
| AAV8-hSyn-flex-miR30-eGFP-shControl | Yu et al., 2015 | N/A |
| **Chemicals, Peptides, and Recombinant Proteins** |        |            |
| Clozapine-N-Oxide | NIMH Chemical Synthesis and Drug Supply Program | C-929 |
| R121919 | Chemical Biology Research Branch- NIAAA-NIDA | N/A |
| Hydroxypropyl-β-cyclodextrin | Sigma Aldrich | H107 |
| Lipofectamine 2000 | Invitrogen | 11668019 |
| Anti-goat secondary antibody, HRP conjugate | Santa Cruz Biotechnology | Cat# sc-2020; RRID:AB_631728 |
| Anti-guinea pig secondary antibody, HRP conjugate | Santa Cruz Biotechnology | Cat# sc-2903; RRID:AB_650493 |
| Fluoromount-G with DAPI | Southern Biotech | 0100–20 |
| Normal donkey serum | Jackson Immunoresearch | 017-000-121 |
| **Critical Commercial Assays** |        |            |
| RNAscope Fluorescent Multiplex Kit | Advanced Cell Diagnostics (ACD) | 320851 |
| RNeasy Lipid Tissue Mini Kit | QIAGEN | 74804 |
| High Capacity cDNA Synthesis Kit | Invitrogen | 4368814 |
| TaqMan Gene Expression Assay Kit | Applied Biosystems | 4331182 |
| Pierce BCA Protein Assay Kit | Thermo Scientific | 23227 |
| **Experimental Models: Cell Lines** |        |            |
| HEK293FT cells (female) | Thermofisher Scientific | R70007 |
| **Experimental Models: Organisms/Strains** |        |            |
| Crh-Cre rats | Pomrenze et al., 2015 | N/A |
| **Oligonucleotides** |        |            |
| TaqMan Crh RNA probe | Applied Biosystems | Rn01462137_m1 |
| TaqMan Pdyn RNA probe | Applied Biosystems | Rn00571351_m1 |
| TaqMan Nts RNA probe | Applied Biosystems | Rn01503265_m1 |
| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| TaqMan GusB RNA probe | Applied Biosystems | Rn00566655_m1 |
| RNAscope Vgat probe | ACD | 424541 |
| RNAscope egfp probe | ACD | 409971 |
| shCdh1: AACACAGTATTCTGTACCATAC | This paper | N/A |
| shCdh2: AAGTGTGTCTCTGTAGTAAC | This paper | N/A |
| shDyn1: TACACTGAGCCTGTTCCTCCAT | This paper | N/A |
| shDyn2: AGCTCTTCATGTGTTCTGAAT | This paper | N/A |
| shNtv1: ACATGTGATTCTCATCCTTTC | This paper | N/A |
| shNtv2: TACCTGTTAATCTGGATACACAT | This paper | N/A |
| Recombinant DNA | pPRIME-CMV-GFP-recipient | Addgene | 11657 |
| | pAAV-hSyn-flex-dsRed-shVgat | Addgene | 67845 |
| Software and Algorithms | FIJI/ImageJ | NIH | [https://imagej.nih.gov/ij](https://imagej.nih.gov/ij) |
| | EthoVision XT | Noldus | [http://www.noldus.com/](http://www.noldus.com/) |
| | Prism 7 | GraphPad Software | [https://www.graphpad.com/](https://www.graphpad.com/) |
| | G*Power | Faul et al., 2007 | N/A |